Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
Clinical trial NCT07498907 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07498907
- Sponsor
- Peking University First Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2029-05-01
- Enrollment
- 192
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.